0 0 0 0 0 0 0 0
Sign Up Today X
Thanks for submitting the form.
Stockreport

Gilead Sciences Arcellx Deal Deepens Oncology Bet And Tests HIV Reliance [Yahoo! Finance]

Gilead Sciences, Inc. (GILD)  More Company Research Source: Yahoo! Finance
Last gilead sciences, inc. earnings: 4/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.gilead.com
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Gilead Sciences has entered a definitive agreement to acquire Arcellx, Inc. in a cash deal valued at $7.8b. The transaction expands Gilead's presence in oncology and cell therapy, areas that differ from its core HIV franchise. For investors watching NasdaqGS:GILD, this move comes as the shares trade around $150.03, with a 1 year return of 33.0% and a 3 year return of 105.6%. Over 5 years, the stock shows a very large gain of 180.7%, and the company currently carries a value score of 4, which may catch the eye of value focused investors. This acquisition reflects Gilead increasing its focus on high value cancer therapies and cell based treatments, which may influence how its business mix develops over time. As the deal progresses, investors will likely watch how Gilead integrates Arcellx's pipeline and capabilities into its existing oncology platform and how [Read more]
IMPACT SNAPSHOT EVENT TIME: GILD
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
GILD alerts
from News Quantified
GILD
NEWS
GILD
Earnings
GILD
Analyst Actions
GILD
SEC Filings
Stockreport

Gilead Sciences Arcellx Deal Deepens Oncology Bet And Tests HIV Reliance [Yahoo! Finance]

Gilead Sciences, Inc.  (GILD) 
More Company Research Source: Yahoo! Finance
Last gilead sciences, inc. earnings: 4/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.gilead.com
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Gilead Sciences has entered a definitive agreement to acquire Arcellx, Inc. in a cash deal valued at $7.8b. The transaction expands Gilead's presence in oncology and cell therapy, areas that differ from its core HIV franchise. For investors watching NasdaqGS:GILD, this move comes as the shares trade around $150.03, with a 1 year return of 33.0% and a 3 year return of 105.6%. Over 5 years, the stock shows a very large gain of 180.7%, and the company currently carries a value score of 4, which may catch the eye of value focused investors. This acquisition reflects Gilead increasing its focus on high value cancer therapies and cell based treatments, which may influence how its business mix develops over time. As the deal progresses, investors will likely watch how Gilead integrates Arcellx's pipeline and capabilities into its existing oncology platform and how [Read more]
IMPACT SNAPSHOT
EVENT TIME:
GILD
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS